ArticleOncoTargets and therapy2019

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation.

Lei Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.